Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immutep Limited

1.54
+0.09006.21%
Post-market: 1.46-0.0780-5.06%17:30 EDT
Volume:12.96K
Turnover:19.58K
Market Cap:224.16M
PE:-7.56
High:1.55
Open:1.47
Low:1.46
Close:1.45
Loading ...

Immutep to Participate in Upcoming Investor Conferences

GlobeNewswire
·
02 Apr

Immutep announces first patient dosed in TACTI-004 Phase III trial

TIPRANKS
·
26 Mar

First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

GlobeNewswire
·
25 Mar

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025

GlobeNewswire
·
20 Mar

Great week for Immutep Limited (ASX:IMM) institutional investors after losing 16% over the previous year

Simply Wall St.
·
20 Mar

Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now?

Insider Monkey
·
12 Feb

Immutep reports Q2 cash receipts from customers A$8,000

TIPRANKS
·
31 Jan

Immutep Quarterly Activities Report Q2 FY25

GlobeNewswire
·
31 Jan

Is Immutep Limited (IMMP) One of the Best ASX Stocks to Buy According to Hedge Funds?

Insider Monkey
·
31 Jan

Why Immutep (IMMP) Is Among the Best Australian Stocks to Buy Now?

Insider Monkey
·
27 Jan

Patient Enrolment Completed for EFTISARC-NEO Phase II Trial

GlobeNewswire
·
22 Jan

Immutep Limited (ASX:IMM) is largely controlled by institutional shareholders who own 51% of the company

Simply Wall St.
·
16 Jan

Patient Enrolment Completed for INSIGHT-003

GlobeNewswire
·
06 Jan

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

GlobeNewswire
·
17 Dec 2024

Immutep, Monash University announce publication on human LAG-3

TIPRANKS
·
16 Dec 2024

Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

GlobeNewswire
·
16 Dec 2024

Immutep announces results from Cohort B of TACTI-003 trial

TipRanks
·
13 Dec 2024

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

GlobeNewswire
·
12 Dec 2024

Immutep announces initiation of TACTI-004 Phase III trial

TIPRANKS
·
10 Dec 2024

Immutep Limited Passes All AGM Resolutions

TIPRANKS
·
22 Nov 2024